Last reviewed: May 16, 2026

Last updated: May 16, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Henry Meds and Reflexmd are both telemedicine platforms offering GLP-1 prescription services, but they operate under different clinical frameworks, cost models, and eligibility requirements. Choosing between them requires understanding how each platform evaluates your candidacy and what clinical data informs their prescribing decisions.

Beyond price and convenience, the most important factor is whether a platform's clinical approach aligns with your health profile. This includes your baseline metabolic markers, cardiovascular risk factors, and genetic predispositions in peptide signaling pathways. Understanding these elements supports more informed conversations with healthcare providers about which option serves your long-term wellness goals.

How Henry Meds and Reflexmd Structure Clinical Eligibility

Henry Meds requires a BMI of at least 27 with a comorbid condition, or BMI 30 or higher regardless of comorbidities. Reflexmd uses similar BMI thresholds but may have more flexible evaluation for metabolic conditions like prediabetes or polycystic ovary syndrome. Both platforms conduct physician-led consultations, though the depth of metabolic assessment varies.

Neither platform routinely orders comprehensive metabolic panels or genetic peptide pathway screening before prescribing. This means your provider may have limited biomarker context when making initial dosing and medication-choice decisions. Understanding your own metabolic baseline—fasting glucose, insulin levels, lipid profile, and inflammatory markers—helps you engage more meaningfully with either provider during consultation.

Cost, Prescription Model, and Long-Term Affordability Comparison

Henry Meds and Reflexmd differ in how they structure monthly fees, medication costs, and follow-up consultations. This table outlines key financial and operational differences that affect total cost of care and treatment continuity.

Factor Henry Meds Reflexmd Considerations for Your Decision
Initial Consultation Typically $150–$250 Typically $100–$200 Both offer first visit through licensed physicians. Follow-up costs vary by platform.
Medication Sourcing Licensed compounding pharmacies; some branded options available Licensed compounding pharmacies; sourcing varies by state Verify that your state permits and your insurance covers the pharmacy model offered.
Ongoing Follow-up Monthly or quarterly check-ins; costs add up Varies; some tiers include follow-ups Long-term affordability depends on consultation frequency. Ask upfront about annual total costs.
Insurance Coverage Limited; most users self-pay or use FSA/HSA Limited; self-pay model typical GLP-1 for weight loss rarely covered by insurance. Budget accordingly for 6–12 months minimum.

Medication Selection: Semaglutide, Tirzepatide, and Dual-Agonist Compounds

Both platforms can prescribe semaglutide and tirzepatide through licensed 503A compounding pharmacies. Henry Meds may offer more branded-drug options depending on location, while Reflexmd focuses primarily on compounded formulations. The choice between weekly injection and oral dosing also affects both cost and adherence patterns over time.

Your response to GLP-1 therapy depends partly on genetic variants in the GLP1R, GIPR, and FTO genes that regulate peptide signaling and appetite control. Neither Henry Meds nor Reflexmd typically screens for these predispositions before prescribing, meaning your provider is making a best-guess initial selection. Understanding your genetic profile can help you and your provider predict which medication class (GLP-1 agonist vs. dual GLP-1/GIP agonist) may yield better metabolic outcomes.

Who Should Choose Each Platform—And When Provider-Led Biomarker Assessment Matters

Henry Meds may suit patients with straightforward BMI-based eligibility, existing metabolic diagnoses (diabetes, prediabetes), and comfort with a larger platform infrastructure. Reflexmd appeals to those seeking lower-cost consultations and faster prescription turnaround. However, neither platform is ideal if you have complex medical history, polypharmacy concerns, or previous poor tolerance to GLP-1 drugs.

Patients with a personal or family history of medullary thyroid cancer, pancreatitis, or gastroparesis should work with a provider who reviews detailed clinical history and baseline labs before starting therapy. Similarly, if you've experienced poor tolerability with one GLP-1 medication, genetic and biomarker context can inform whether a different compound class might work better. This level of clinical depth is not standard on either platform, making a hybrid approach—platform prescription plus genetic testing and biomarker review—increasingly valuable.

How PlexusDx Supports a More Personalized Approach

PlexusDx recognizes that comparing platforms like Henry Meds and Reflexmd requires more than pricing—it requires understanding your individual biomarker and genetic context. Our Precision Peptide Genetic Test may help provide context about your predispositions in key peptide signaling pathways, including GLP1R, GIPR, FTO, and MC4R variants. This information should be interpreted with a qualified healthcare provider to inform both platform selection and medication choice.

The Precision Peptide Genetic Test ($99 add-on or $298 standalone) reveals predispositions in peptide genetic pathways that influence how your body responds to GLP-1 and GIP-based therapies. Key variants such as GLP1R rs6923761 and GIPR rs1800437 may help explain why some patients achieve robust weight loss and metabolic improvements while others experience slower responses or higher side effect burden. This test does not predict exact medication response but provides clinically relevant context that supports more personalized treatment planning.

Whether you choose Henry Meds, Reflexmd, or another platform, layering biomarker and genetic assessment into your decision-making process can support a more informed conversation with your provider. Understanding your FTO rs9939609 and MC4R rs17782313 variants, combined with baseline metabolic labs, helps you and your healthcare team set realistic expectations and adjust therapy with greater precision. This data-driven approach moves beyond one-size-fits-all prescribing toward treatment aligned with your unique physiology.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Microdose Glp1 Protocol starts at $129/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the main difference between Henry Meds and Reflexmd eligibility?

Henry Meds requires BMI 27+ with comorbidity or BMI 30+ alone; Reflexmd uses similar thresholds but may evaluate metabolic conditions more flexibly. Both require physician consultation. Exact requirements vary by state and individual health profile.

Are compounded medications from either platform FDA-approved?

Compounded semaglutide and tirzepatide are not FDA-approved as branded drugs. They are prepared by licensed 503A pharmacies under physician prescription. Quality and sterility standards vary; verify your pharmacy's licensing and state board approval before starting treatment.

How does PlexusDx pricing compare, and do you work with Henry Meds or Reflexmd?

PlexusDx offers compounded semaglutide ($149/mo), oral semaglutide ($249/mo), and compounded tirzepatide ($249/mo) through licensed 503A pharmacies. We operate independently; our Precision Peptide Genetic Test ($99 add-on or $298 standalone) can support your conversation with any provider, including those at Henry Meds or Reflexmd.

What should I know about side effects before choosing a platform?

GLP-1 side effects—nausea, vomiting, constipation, dehydration—occur in 30–50% of users and often improve with time or dose adjustment. Rare but serious risks include pancreatitis and gallbladder issues. Your medical history should guide which platform and medication are safest for you; discuss previous medication tolerability with your provider.

Can genetic testing help me choose between semaglutide and tirzepatide?

Your Precision Peptide Genetic Test results—particularly GLP1R and GIPR variants—may help provide context about your predispositions in peptide signaling.

Related Reading

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves